Prosidyan Develops Fiber-Based Bioactive Glass Bone Graft Substitute Product Line FIBERGRAFT

September 13 2021

Prosidyan, Inc., developer of proprietary fiber-based bioactive glass bone graft substitute products, targets the Orthopedic Trauma Market with its FIBERGRAFT BG product line. FIBERGRAFT BG products have been commercially available for over seven years and have been successfully implanted in patients worldwide.
FIBERGRAFT BG products are next generation synthetic bioactive bone graft substitutes used to assist in the healing of surgically created osseous defects and osseous defects created from traumatic injury to the bone. The clinically-proven FIBERGRAFT BG products are manufactured with proprietary bioactive glass fibers that recruit bone-forming cells, attach these cells to its scaffold and connect them for cell proliferation– all of which enables robust bone formation.
For identifying Growth Opportunities for the Glass Fiber Market please visit https://www.lucintel.com/glass-fiber-market.aspx

Lucintel Corporate Customers

Market Entry, M & A, Opportunity Screening,...

Private Equity Customers

Buy Side Services (target screening, due diligence, ..)

Customer Quotes

"With more than 20 years experience in the industry, this is the first time we have come across such an extensive market analysis for our industry." Ven Cote, CEO, ZCL

"The insights we gained from Lucintel work helped with our business plan…a wonderful professional job…" Mike Jackson, Stahlin

"The report from Lucintel is useful not only for business planners, but also for the technology officers wanting to create a roadmap …" Dr. Giulio Ranzo, Booz Allen

"The information is so comprehensive, it has allowed us to identify & focus our business development efforts. It saved months of leg-work." Bill Barz, L&L Products

"We bought Lucintel report because it is the best report about our industry…a complete and appropriate analysis." Cesare Andrenacci, Ferretti